RCM
HBIO icon

Rotella Capital Management’s Harvard Bioscience HBIO Stock Holding History

Rotella Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,095
Closed -$119K – 542
2014
Q4 		$119K Sell
2,095
-1,086
-34% -$51.8K 0.1% 221
2014
Q3 		$130K Buy
3,181
+784
+33% +$36.1K 0.14% 145
2014
Q2 		$109K Buy
+2,397
New +$101K 0.09% 206

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Rotella Capital Management's HBIO Position: Q1 2015 in Review

Rotella Capital Management sold out of Harvard Bioscience (HBIO) in Q1 2015, closing a stake of 2,095 shares — an estimated $119K sold.

Rotella Capital Management first reported a position in HBIO in Q2 2014 and held it in 3 quarters. The position peaked at $130K in Q3 2014. 79 funds tracked by Wall St. Rank hold HBIO as of Q1 2015.

  • Rotella Capital Management reported no remaining Harvard Bioscience position as of Q1 2015 after selling out during the quarter.
  • Rotella Capital Management sold 2,095 Harvard Bioscience shares in Q1 2015, an estimated $119K.
  • Rotella Capital Management first reported a position in Harvard Bioscience in Q2 2014 and held it in 3 quarters.
  • Rotella Capital Management's Harvard Bioscience position peaked at $130K in Q3 2014.
  • 79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2015.

Based on Rotella Capital Management's 13F filing for Q1 2015, filed 4 May 2015.